ArticleAnatolian journal of cardiology2025
MiR-107 as a Biomarker Predicts Cardiac Hypertrophy in Chronic Hemodialysis Patients.
Article in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaintenance hemodialysis (MHD) can lead to hypertrophy of myocardial cells and interstitial fibrosis in patients, which can ultimately culminate in left ventricular hypertrophy (LVH). The objective of this study is to examine the expression of miR-107 in patients undergoing MHD who also present with LVH and to evaluate its predictive value.
methodsA total of 135 patients with end-stage renal disease who were undergoing MHD were included as the research subjects. Patients were grouped based on left ventricular mass index. Real-time quantitative polymerase chain reaction was used to detect the expression of miR-107 in the serum of the patients. The receiver operating characteristic curve was used to evaluate the diagnostic value of miR-107 in MHD with LVH patients. The Pearson's method was used for correlation analysis. Logistic regression model was used to analyze the risk factors for cardiac hypertrophy in MHD patients.
resultsSerum miR-107 is highly expressed in patients with MHD and LVH, and it may be a potential diagnostic biomarker. miR-107 has relatively high sensitivity and specificity in predicting LVH in patients with MHD. Serum miR-107 is closely related to the serum high-sensitivity C-reactive protein level and echocardiographic characteristics of patients with MHD combined with LVH. MiR-107 correlates with echocardiographic characteristics of MHD patients with LVH. Finally, logistic regression analysis indicated that miR-107 was a risk factor for LVH in MHD patients.
conclusionSerum miR-107 may have significant potential in diagnosing cardiac hypertrophy in MHD patients and is a potential biological indicator for cardiac hypertrophy in MHD patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.